SOURCE-LINKED STUDY SUMMARY
Metabolic benefits of ketohexokinase inhibition in individuals with MASLD: a randomized placebo-controlled crossover trial.
Abstract summarizedQuality not appraised
- What was studied
- A crossover trial tested inhibition of fructose metabolism in fatty liver disease.
- Who / model studied
- 15 participants with metabolic dysfunction-associated steatotic liver disease.
- Studied dose & schedule
- Oral PF-06835919 300 mg daily versus placebo for six weeks per treatment period; route and dose verified in the trial registry.
- What the study found
- Hepatic insulin sensitivity improved on the primary endpoint. Liver lipid, peripheral glucose disposal and nocturnal fat oxidation also improved. Body weight did not change.
- Limitations & context
- Small, short disease-population trial. Does not demonstrate healthy-person fat loss or long-term clinical benefit. Numerical effect sizes and adverse-event counts were unavailable in the abstract.
Read summary source ↗ · Prepared 10/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1038/s42255-026-01626-5